
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6542697/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pasta Structure Affects Mastication, Bolus Properties, and Postprandial Glucose and Insulin Metabolism in Healthy Adults. Journal of Nutrition, 2022, 152, 994-1005.	2.9	16
2	SARS-CoV-2 Spike protein is not pro-inflammatory in human primary macrophages: endotoxin contamination and lack of protein glycosylation as possible confounders. Cell Biology and Toxicology, 2022, 38, 667-678.	5.3	10
3	Do the Current Guidelines for Heart Failure Diagnosis and Treatment Fit with Clinical Complexity?. Journal of Clinical Medicine, 2022, 11, 857.	2.4	18
4	Empagliflozin does not reverse lipotoxicity-induced impairment in human myeloid angiogenic cell bioenergetics. Cardiovascular Diabetology, 2022, 21, 27.	6.8	1
5	Effect of coffee and cocoa-based confectionery containing coffee on markers of cardiometabolic health: results from the pocket-4-life project. European Journal of Nutrition, 2021, 60, 1453-1463.	3.9	12
6	Metabolomic Changes after Coffee Consumption: New Paths on the Block. Molecular Nutrition and Food Research, 2021, 65, 2000875.	3.3	11
7	Effect of Coffee and Cocoa-Based Confectionery Containing Coffee on Markers of DNA Damage and Lipid Peroxidation Products: Results from a Human Intervention Study. Nutrients, 2021, 13, 2399.	4.1	5
8	Effect of different patterns of consumption of coffee and a cocoa-based product containing coffee on the nutrikinetics and urinary excretion of phenolic compounds. American Journal of Clinical Nutrition, 2021, 114, 2107-2118.	4.7	12
9	Absorption, Pharmacokinetics, and Urinary Excretion of Pyridines After Consumption of Coffee and Cocoaâ€Based Products Containing Coffee in a Repeated Dose, Crossover Human Intervention Study. Molecular Nutrition and Food Research, 2020, 64, e2000489.	3.3	15
10	A performance score of the quality of inpatient diabetes care is a marker of clinical outcomes and suggests a causeâ€effect relationship between hypoglycaemia and the risk of inâ€hospital mortality. Diabetes/Metabolism Research and Reviews, 2020, 36, e3347.	4.0	2
11	Prevalence of orthorexic traits in type 2 diabetes mellitus: at the crossroads between nutritional counseling and eating disorders. Acta Diabetologica, 2020, 57, 1117-1119.	2.5	9
12	Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events. Cardiovascular Diabetology, 2020, 19, 46.	6.8	43
13	Dysfunctional eating in type 2 diabetes mellitus: A multicenter Italian study of socio-demographic and clinical associations. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 983-990.	2.6	12
14	Similar effectiveness of dapagliflozin and GLPâ€1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study. Diabetes, Obesity and Metabolism, 2019, 21, 1886-1894.	4.4	17
15	The role of physical activity in individuals with cardiovascular risk factors: an opinion paper from Italian Society of Cardiology-Emilia Romagna-Marche and SIC-Sport. Journal of Cardiovascular Medicine, 2019, 20, 631-639.	1.5	43
16	Cardiovascular prevention in women: a narrative review from the Italian Society of Cardiology working groups on †Cardiovascular Prevention, Hypertension and peripheral circulation' and on †Women Disease†M. Journal of Cardiovascular Medicine, 2019, 20, 575-583.	1.5	49
17	Claimed effects, outcome variables and methods of measurement for health claims on foods related to the gastrointestinal tract proposed under regulation (EC) 1924/2006. International Journal of Food Sciences and Nutrition, 2018, 69, 771-804.	2.8	6
18	Claimed effects, outcome variables and methods of measurement for health claims proposed under Regulation (EC) 1924/2006 in the framework of bone health. PharmaNutrition, 2018, 6, 17-36.	1.7	4

#	Article	IF	CITATIONS
19	Claimed effects, outcome variables and methods of measurement for health claims on foods proposed under Regulation (EC) 1924/2006 in the area of oral health. NFS Journal, 2018, 10, 10-25.	4.3	7
20	Claimed effects, outcome variables and methods of measurement for health claims on foods proposed under European Community Regulation 1924/2006 in the area of appetite ratings and weight management. International Journal of Food Sciences and Nutrition, 2018, 69, 389-409.	2.8	13
21	CP/EFSA/NUTRI/2014/01 Scientific substantiation of health claims made on food: collection, collation and critical analysis of information in relation to claimed effects, outcome variables and methods of measurement. EFSA Supporting Publications, 2018, 15, 1272E.	0.7	1
22	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology. European Heart Journal, 2018, 39, 4243-4254.	2.2	171
23	Claimed Effects, Outcome Variables and Methods of Measurement for Health Claims Proposed Under European Community Regulation 1924/2006 in the Framework of Maintenance of Skin Function. Nutrients, 2018, 10, 7.	4.1	18
24	Claimed Effects, Outcome Variables and Methods of Measurement for Health Claims on Foods Related to Vision Proposed Under Regulation (EC) 1924/2006. Nutrients, 2018, 10, 211.	4.1	0
25	Claimed effects, outcome variables and methods of measurement for health claims proposed under European Community Regulation 1924/2006 in the area of blood glucose and insulin concentrations. Acta Diabetologica, 2018, 55, 391-404.	2.5	2
26	Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes. Cardiovascular Diabetology, 2017, 16, 27.	6.8	35
27	Mediterranean diet impact on cardiovascular diseases. Journal of Cardiovascular Medicine, 2017, 18, 925-935.	1.5	55
28	Stearic acid at physiologic concentrations induces inÂvitro lipotoxicity in circulating angiogenic cells. Atherosclerosis, 2017, 265, 162-171.	0.8	19
29	Effects of a New Nutraceutical Formulation (Berberine, Red Yeast Rice and Chitosan) on Non-HDL Cholesterol Levels in Individuals with Dyslipidemia: Results from a Randomized, Double Blind, Placebo-Controlled Study. International Journal of Molecular Sciences, 2017, 18, 1498.	4.1	49
30	Identification of an early transcriptomic signature of insulin resistance and related diseases in lymphomonocytes of healthy subjects. PLoS ONE, 2017, 12, e0182559.	2.5	11
31	Bioavailability of Bergamot (Citrus bergamia) Flavanones and Biological Activity of Their Circulating Metabolites in Human Pro-Angiogenic Cells. Nutrients, 2017, 9, 1328.	4.1	23
32	Performance and antrhropometric characteristics of Elite Rugby Players. Acta Biomedica, 2017, 88, 172-177.	0.3	6
33	Effects on Nitric Oxide Production of Urolithins, Gut-Derived Ellagitannin Metabolites, in Human Aortic Endothelial Cells. Molecules, 2016, 21, 1009.	3.8	37
34	Telomere length is independently associated with subclinical atherosclerosis in subjects with type 2 diabetes: a cross-sectional study. Acta Diabetologica, 2016, 53, 661-667.	2.5	18
35	Novel insight into the dangerous connection between diabetes and heart failure. Herz, 2016, 41, 201-207.	1.1	12
36	The β-cell burden index of food: A proposal. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 872-878.	2.6	3

#	Article	IF	CITATIONS
37	Effects of TiO2 and Co3O4 Nanoparticles on Circulating Angiogenic Cells. PLoS ONE, 2015, 10, e0119310.	2.5	20
38	Transcriptomic Analysis of Human Polarized Macrophages: More than One Role of Alternative Activation?. PLoS ONE, 2015, 10, e0119751.	2.5	70
39	Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients WithÂHeart Failure. JACC: Heart Failure, 2015, 3, 136-145.	4.1	265
40	Effects of oral administration of orodispersible levo-carnosine on quality of life and exercise performance in patients with chronic heart failure. Nutrition, 2015, 31, 72-78.	2.4	56
41	Concomitant Diabetes Mellitus and Heart Failure. Current Problems in Cardiology, 2015, 40, 7-43.	2.4	75
42	Research update for articles published in EJCI in 2012. European Journal of Clinical Investigation, 2014, 44, 1010-1023.	3.4	1
43	Mineralocorticoid Receptor Antagonist Use in Hospitalized Patients With Heart Failure, Reduced Ejection Fraction, and Diabetes Mellitus (from the EVEREST Trial). American Journal of Cardiology, 2014, 114, 743-750.	1.6	8
44	N-3 PUFA increase bioavailability and function of endothelial progenitor cells. Food and Function, 2014, 5, 1881.	4.6	26
45	Reduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and/or diabetic patients. A meta-regression analysis of 32 randomized trials. International Journal of Cardiology, 2014, 172, 403-410.	1.7	36
46	Lower endothelial progenitor cell number, family history of cardiovascular disease and reduced HDL-cholesterol levels are associated with shorter leukocyte telomere length in healthy young adults. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 272-278.	2.6	37
47	Diabetes and Chronic Heart Failure: From Diabetic Cardiomyopathy to Therapeutic Approach. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2013, 13, 38-50.	1.2	29
48	Synchronous cryptogenic liver cirrhosis and idiopathic pulmonary fibrosis: A clue to telomere involvement. Hepatology, 2012, 56, 2001-2003.	7.3	23
49	VEGF and angiopoietins in diabetic glomerulopathy: How far for a new treatment?. Metabolism: Clinical and Experimental, 2012, 61, 1666-1673.	3.4	37
50	Pioglitazone Improves In Vitro Viability and Function of Endothelial Progenitor Cells from Individuals with Impaired Glucose Tolerance. PLoS ONE, 2012, 7, e48283.	2.5	41
51	Sixâ€year prognosis of diabetic patients with coronary artery disease. European Journal of Clinical Investigation, 2012, 42, 376-383.	3.4	12
52	Use of Inotropic Agents in Patients with Advanced Heart Failure. Drugs, 2011, 71, 515-525.	10.9	15
53	Reduced circulating endothelial progenitor cell number in healthy young adult hyperinsulinemic men. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 512-517.	2.6	18
54	Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure. Journal of Cardiovascular Medicine, 2011, 12, 76-84.	1.5	56

#	Article	IF	CITATIONS
55	Effect of Spironolactone on Left Ventricular Ejection Fraction and Volumes in Patients With Class I or II Heart Failure. American Journal of Cardiology, 2010, 106, 1292-1296.	1.6	63
56	Nebivolol. Drugs, 2010, 70, 41-56.	10.9	52
57	Mechanical forces and TGFÂ1 reduce podocyte adhesion through Â3Â1 integrin downregulation. Nephrology Dialysis Transplantation, 2009, 24, 2645-2655.	0.7	79
58	Inducible Overexpression of sFlt-1 in Podocytes Ameliorates Glomerulopathy in Diabetic Mice. Diabetes, 2008, 57, 2824-2833.	0.6	96
59	Podocyte-Specific Expression of Angiopoietin-2 Causes Proteinuria and Apoptosis of Glomerular Endothelia. Journal of the American Society of Nephrology: JASN, 2007, 18, 2320-2329.	6.1	143
60	Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: A multicenter, randomized, double-blind study. Thrombosis Research, 2007, 119, 85-91.	1.7	19
61	Prevention and management of chronic heart failure in patients at risk. American Journal of Cardiology, 2003, 91, 10-17.	1.6	20
62	Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus. European Journal of Heart Failure, 2003, 5, 803-809.	7.1	20